Video

Case Presentation: A 74-Year-Old Man With Metastatic Prostate Cancer

Author(s):

Neal Shore, MD, FACS

Neal Shore, MD, FACS, presents the case of a 74-year-old man diagnosed with metastatic prostate cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Post-RP incontinence: Low procedure rates examined
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Related Content
      Patient talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      July 10th 2025

      FDA grants breakthrough device designation for ArteraAI Prostate tool

      Benjamin P. Saylor Hannah Clarke
      “This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC
      July 9th 2025

      FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

      Benjamin P. Saylor Hannah Clarke
      The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Expanded indication sought for niraparib plus AAP in Europe
      July 7th 2025

      Expanded indication sought for niraparib plus AAP in Europe

      Hannah Clarke
      The application is supported by data from the phase 3 AMPLITUDE trial.
      Regulatory recap: FDA approvals in urology from the first half of 2025
      July 4th 2025

      Regulatory recap: FDA approvals in urology from the first half of 2025

      Hannah Clarke
      Take a look through all the regulatory milestones in urology from the first half of the 2025.
      © 2025 MJH Life Sciences

      All rights reserved.